Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay

Transfusion

Volumn 53, Issue 10 PART 2, 2013, Pages 2477-2488

  Tsoi, Wai Chiu ^a,b   Lelie, Nico ^a,b   Lin, Che Kit ^a,b  

^a Hong Kong Red Cross Blood Transfusion Service   (Hong Kong)

^b Lelie Research   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

BLOOD; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION; CLASSIFICATION; COMPARATIVE STUDY; EVALUATION STUDY; GENETIC TRANSCRIPTION; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HONG KONG; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MASS SCREENING; NUCLEIC ACID AMPLIFICATION; PHYSIOLOGY; PROCEDURES; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STANDARDS; STATISTICS AND NUMERICAL DATA; TOTAL QUALITY MANAGEMENT; TRANSMISSION; WORLD HEALTH ORGANIZATION; ARTICLE; DISEASE TRANSMISSION; EPIDEMIOLOGY; METHODOLOGY; STANDARD; STATISTICS;

BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HONG KONG; HUMANS; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; QUALITY IMPROVEMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES; TRANSCRIPTION, GENETIC; WORLD HEALTH ORGANIZATION;

EID: 84891684516     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12165     Document Type: Article

References (36)

1. Tse S, Ho CF, Tse IC, Wong KH. Surveillance of viral hepatitis in Hong Kong-2009 update report. Special Preventive Programme, Centre for Health Protection, Department of Health, Hong Kong. December 2010. [cited 2012 Mar 5]. Available from: URL: http://www.info.gov.hk/hepatitis/doc/hepsurv09.pdf
2. Yuen MF, Sablon E, Tanaka Y, Kato T, Mizokami M, Doutreloigne J, Yuan HJ, Wong DK, Sum SM, Lai CL. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. J Hepatol 2004;41:119-25.
3. Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004;2:941-5.
4. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006;91:1-12.
5. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
6. Tsoi WC, Lee CK, Lin CK. Estimation of incidence and residual risk of transfusion transmitted infection for HIV, HCV and HBV in Hong Kong: 2007-2009 (Abstract P-158). Vox Sang 2011;101 Suppl s2:83.
7. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-98.
8. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006;36 Suppl 1:S23-9.
9. Allain JP, Candotti D. Diagnostic algorithm for HBV safe transfusion. Blood Transfus 2009;7:174-82.
10. Zahn A, Li C, Danso K, Candotti D, Owusu-Ofori S, Temple J, Allain JP. Molecular characterization of occult hepatitis B virus in genotype E-infected subjects. J Gen Virol 2008;89: 409-18.
11. Vermeulen M, Dickens C, Lelie N, Walker E, Coleman C, Keyter M, Reddy R, Crookes R, Kramvis A. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2012;52:88-92.
12. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Zoulim F et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
13. Manzini P, Abate ML, Valpreda C, Milanesi P, Curti F, Rizzetto M, Smedile A. Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor. Transfusion 2009;49:757-64.
14. Weusten J, Vermeulen M, van Drimmelen H, Lelie N. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011;51:203-15.
15. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K. Hepatitis-B virus NAT positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005;88:77-86.
16. Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, Shimada T, Miyakawa Y, Yoshizawa H. Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol 2008;80:2064-8.
17. Korelitz JJ, Busch MP, Kleinman SH, Williams AE, Gilcher RO, Ownby HE, Schreiber GB. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997;37:634-40.
18. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, van Drimmelen H, David B, Lelie N, De Micco P. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009;49: 301-10.
19. Minegishi K, Yoshikawa A, Kishimoto S, Yugi H, Yokoya N, Sakurada M, Kiyokawa H, Nishioka K; Japanese Red Cross NAT Screening Research Group. Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. Vox Sang 2003;84:287-91.
20. Komiya Y, Katayama K, Yugi H Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008;48: 286-94.
21. Vermeulen M, Coleman C, Lelie N, Van Drimmelen H, Reddy R. Enhancement of HBV NAT yield after introduction of the Ultrio Plus assay. (Abstract P-295). Vox Sang 2012;103 Suppl 1:161.
22. Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013;53:1405-15.
23. Vermeulen M, Coleman C, Mitchel J, Reddy R, Van Drimmelen H, Ficket T, Lelie N. A Mathematical approach to determine efficacy of NAT in removing transmission risk of occult HBV infection by blood components (Abstract 3C-S12-03). Vox Sang 2012;103 Suppl 1:18-9.
24. Allain JP, Belkhiri D, Vermeulen M, Crookes R, Cable R, Amiri A, Reddy R, Bird A, Candotti D. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 2009;49:1868-76.
25. Candotti D, Grabarczyk P, Ghiazza P, Roig R, Casamitjana N, Iudicone P, Schmidt M, Bird A, Crookes R, Brojer E, Miceli M, Amiri A, Li C, Allain JP. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 2008;49:537-47.
26. Candotti D, Lin CK, Belkhiri D, Sakuldamrongpanich T, Biswas S, Lin S, Teo D, Ayob Y, Allain JP. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence. Gut 2012;61:1744-53.
27. Zheng X, Ye X, Zhang L, Wang W, Shuai L, Wang A, Zeng J, Candotti D, Allain JP, Li C. Characterization of occult hepatitis B virus infection from blood donors in China. J Clin Microbiol 2011;49:1730-7.
28. Li L, Chen PJ, Chen MH, Chak KF, Lin KS, Tsai SJ. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. Transfusion 2008;48:1198-206.
29. Louisirirotchanakul S, Oota S, Khuponsarb K, Chalermchan W, Phikulsod S, Chongkolwatana V, Sakuldamrongpanish T, Kitpoka P, Chielsilp P, Tanprasert S, Tirawatnapong T, Wasi C; Working Group for NAT Study in Thai Blood Donations. Occult hepatitis B virus infection in Thai blood donors. Transfusion 2011;51:1532-40.
30. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364:236-47.
31. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ; German Red Cross NAT Study Group. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008;48:1558-66.
32. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008;48:1022-5.
33. Yoshikawa A, Gotanda Y, Minegishi K, Taira R, Hino S, Tadokoro K, Ohnuma H, Miyakawa K, Tachibana K, Mizoguchi H; the Japanese Red Cross NAT Screening Research Group. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007;47:1162-71.
34. Bremer CM, Saniewski M, Wend U, Torres P, Lelie PN, Gerlich WH, Glebe D. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 2009;49:1621-29.
35. Gerlich WH, Glebe D, Schüttler CG. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Virol Hepatol 2007;14 Suppl 1:16-21.
36. El Ekiaby M, Allain JP, Linnen J, Lelie N. Hepatitis B virus DNA and hepatitis B surface antigen concentrations in Egyptian blood donors; limits of detection of ultrasensitive nucleic acid screening tests in HBsAg carriers. (Abstract 2A-S04-02). Vox Sang 2009;96 Suppl 1:17-8.